Navigation Links
Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026
Date:6/14/2016

LONDON, June 14, 2016 /PRNewswire/ --

Revenue Forecasts for Leading Submarkets Including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and Also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif 

MS Drugs - Discover R&D Trends and Markets With Highest Revenue Potentials

Where is the multiple sclerosis drugs market heading? Visiongain's new study predicts that pharma industry's revenues from 2016. There you find potentials for sales growth, also exploring trends, technologies, patients' needs and opportunities.

Our report gives you revenue forecasts to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data. Instead see what is happening for those central nervous system (CNS) drugs, hearing how you can gain in knowledge and benefit your influence.

Please read on to explore those therapies and discover what revenue their future market could generate.

Forecasts to 2026 and other analysis show you commercial prospects 

Besides revenue forecasting to 2026, our new study shows you historical and epidemiological data, growth rates and market shares. See progress in products and clinical trials, exploring what the future holds. And you get 81 tables and 48 charts.

With our study you assess trends, demands and sales potentials for MS-treating medicines. You see, from 2016, where needs and money exist. Discover the most lucrative market segments and products, including conventional drugs and biologics.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

The following sections explain how you benefit from our new investigation.

Forecasts from 2016 for the world MS medicines market and submarkets 

What are the secrets of that industry's progress? See expected trends there. Along with prediction of the overall world market for treating multiple sclerosis, our report shows you revenue forecasting of five therapeutic submarkets to 2026 at world level:
• Monoclonal antibodies (mAbs)
• S1PR modulators
• Interferons
• Other immunomodulators
• Other agents.

Our analyses and discussions show you commercial potentials for MS-treating medicines, present and future. Discover those opportunities for improved treatment.

With our study you get the forecasting leaders need, benefiting your authority. Our study's purpose is to help your research, analyses and decisions.

There, in our work, you also find revenue predictions for leading products.

Predictions of leading products' sales - what is possible for those CNS drugs?
 

How will individual multiple sclerosis medicines perform to 2026 at world level? Our new report shows revenue forecasts to 2026 for 10 leading marketed drugs and three promising candidates in the R&D pipeline:
• Copaxone (glatiramer acetate) by Teva Pharmaceutical Industries
• Tecfidera (dimethyl fumarate) by Biogen
• Avonex (interferon beta-1a) by Biogen
• Gilenya (fingolimod) by Novartis
• Rebif (interferon beta-1a) by Merck KGaA
• Tysabri (natalizumab) by Biogen
• Betaseron/Betaferon (interferon beta-1b) by Bayer
• Aubagio (teriflunomide) by Sanofi
• Plegridy (peginterferon beta-1a) by Biogen
• Lemtrada (alemtuzumab) by Sanofi
• Ocrelizumab (Ocrevus / RG1594) by Roche
• Ozanimod by Celgene
• Zinbryta (daclizumab high-yield process) by Biogen and AbbVie.

In our study you see how high sales can go, finding products and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, exploring challenges, trends, competitors and opportunities.

Discover what the future holds for treating multiple sclerosis. Our work also shows you geographical predictions by leading country.

National and regional markets - what outlooks for demand and sales? 

In developed and developing countries, opportunities for MS drug developers and producers will occur from 2016, leading to revenue gains. Find the most promising markets.

Our investigation shows revenue forecasts to 2026 for 10 leading national markets for multiple sclerosis drugs:
• US
Japan
Canada
Germany, France, UK, Italy and Spain
India and China.

There you explore progress and outlooks. You assess that those medicines' future - hear about developments, also finding their meaning and sales potentials.

That way you find opportunity and assess challenges. Our work explains what the future holds, exploring issues affecting those pharmaceutical companies.

Forces affecting MS drug producers and the healthcare needs they serve
 

Our report shows you activities, developments and events affecting that industry and market from 2016, including these influences:
• Demographics and geographical distribution
• Prevalence and incidence of multiple sclerosis
• Disease modifying treatments
• Immunomodulators, monoclonal antibodies, S1PR modulation and other drug classes on the market and in development
• Challenges from generics and biosimilars
• Patent protection and regulatory affairs.

With our survey you explore political, economic, social and technological questions, assessing outlooks for business. You examine forces stimulating and restraining that pharmaceutical market.

You also assess the most promising aspects of that industry's research and development. Discover what that pharma sector's present and future hold.

Leading companies and overall 2020 market value - how high can sales go?
What is possible there? Our analysis predicts the overall world market for MS drugs will reach $23.2 billion in 2020. It will show revenue expansion from 2016 to 2026, giving companies high commercial potentials.

In particular our study explores activities, capabilities and results of these firms:
• Biogen
• Teva Pharmaceutical Industries
• Novartis
• Merck KGaA
• Bayer
• Sanofi
• Roche
• Celgene.

In our work you assess companies' results, strengths and outlooks. So discover where that industry heads, helping you stay ahead in knowledge and succeed.

5 main ways Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026 helps - gain data found nowhere else
Our new investigation helps you in these five main ways, benefiting your research, plans, decisions and presentations:
• Revenues to 2026 for MS drugs at overall world level - explore commercial potentials for companies, their drug development and products
• Prospects of 5 therapeutic submarkets and 13 drugs to 2026 - discover the revenue generating potentials of existing and expected MS medicines
• Forecasts to 2026 for 10 national markets in North America, Europe and Asia - investigate developed and developing countries' revenue potentials
• Outlooks for established and rising MS drug companies - assess portfolios, results and prospects of developers, producers and marketers
• Analysis of what stimulates and restrains that large, expanding pharma market - explore that segment's trends, helping you compete and succeed.

That report, by our in-house analysts in the UK, could benefit your reputation for knowledge, helping you succeed. Gain analysis leading companies depend on.

Data found nowhere else, helping your research, assessments and planning

Our new report gives you independent analysis. You receive business intelligence found only in our work. With that study you are less likely to fall behind in data or miss opportunity. Instead discover what the future holds for your business.

That way discover where prospects and money exist. Our investigation's purpose is to benefit your research, analysis and decisions, also saving you time and effort.

Prospects for drugs treating multiple sclerosis - explore that market's future
Our new study is for everyone investigating the potential of existing and new CNS drugs. There, for MS, you find revenue forecasting from 2016, seeing trends, progress and discussions. Avoid missing out - please get our report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on  https://www.visiongain.com/Report/1656/Multiple-Sclerosis-Drugs-Market-and-R-D-Outlook-2016-2026

Companies mentionned 

AB Science
AbbVie
Actelion
Active Biotech
Apotex
Bayer
Biogen
Canadian Institute for Health Information (CIHI)
Celgene
Clinicaltrials.gov
Committee for Medicinal Products for Human Use (CHMP)
Department of Health and Association of the British Pharmaceutical Industry
Elan
EMA
FDA
Genentech
Genzyme
German Institute for Quality and Efficiency in Health Care (IQWiG)
GSK
Independent Data Safety Monitoring Committee (IDMC)
Independent Payment Advisory Board
Italian National Health Service
Managed Care Magazine
MedDay
Medicare
Medscape
Merck KGaA
Momenta
MS International Federation
Multiple Sclerosis Society of Canada
Mylan
National Institute for Health and Care Excellence (NICE)
Neurology
NHS
Novartis
Population Reference Bureau
Receptos
Reuters
Roche
Sandoz
Sanofi
Swiss Re
Teva Pharmaceutical Industries

The European Commission (EC)
The European Federation of Pharmaceutical Industries and Associations (EFPIA)
The Lancet Neurology
The MS Society
The Multiple Sclerosis Foundation
Torrent Pharmaceuticals
United States National Multiple Sclerosis Society
US Patent Trial and Appeal Board
Wall Street Journal
WHO

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com


'/>"/>
SOURCE Visiongain Ltd
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. New Article Sets Out 10 Vital Calls to Action Needed to Address Shortcomings and Inconsistencies in Multiple Sclerosis Management and New Treatment Development Across Europe
2. PharmaMar Reports Positive Results from the Phase I Study of plitidepsin in Combination with bortezomib and dexamethasone in Patients with Multiple Myeloma at the 2016 ASCO Annual Meeting
3. Global Multiple Myeloma Market and Competitive Landscape 2016 - Forecasts to 2020 - Research and Markets
4. Asia-Pacific Multiple Myeloma Therapeutics Markets to 2021 - Market Value Will Reach $2.8 Billion - Research and Markets
5. Diplomat Celebrates Multiple Sclerosis Week with National Campaign
6. ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms
7. New Review of Vitamin D Deficiency and the Possible Role in Multiple Sclerosis
8. Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain
9. New Studies Presented At American Society Of Hematology Meeting Continue To Demonstrate Efficacy Of Immunotherapy In Aggressive Lymphoma, Hodgkins Lymphoma, Multiple Myeloma
10. Novation Awards Multiple Contracts to Breg
11. Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology:
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):